Transaction Information
SEK 350 million
Financial Adviser
About Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology.
Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmacept.com and www.maglebiopolymers.com.
Website: https://maglegroup.com/
SEK 350m Capital Raise (Senior Secured Bonds)
Q2 2025
SEK 17.5m Capital Raise
Q2 2025
SEK 30m Capital Raise
Q2 2025
SEK 50m Capital Raise
Q2 2025
SEK 61,5m Capital Raise
Q2 2025
SEK 59,5m Capital Raise
Q2 2025
SEK 30m Capital Raise
Q2 2025
SEK 115m Capital Raise
Q2 2025
SEK 25m Capital Raise
Q1 2025
SEK 26.6m Capital Raise
Q4 2024
SEK 280m Capital Raise
Q4 2024
SEK 36.8m Capital Raise
Q4 2024